Souhaitez-vous accéder aux communiqués récents ?

Dr Tayton-Martin brings broad experience of biotech company building, fund-raising, M&A, business development and operations with a strong track record of strategic partnership dealsHer more than...

Austin, Texas, October 25, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, announced analyses data from its Phase 3 COMPETE trial in patients with Grade...

ROCKVILLE, Md., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to...

TORONTO and HOUSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the...

IMNN-001 program is currently advancing its OVATION 3 pivotal Phase 3 trial per plan LAWRENCEVILLE, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in...

Outstanding measure of efficacy relative to high-risk cancers with limited treatment options CHICAGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the...

Basel, 23. Oktober 2025 Konzernverkäufe stiegen in den ersten neun Monaten um 7%1 zu konstanten Wechselkursen (CER; 2% in CHF) aufgrund hoher Nachfrage nach innovativen Medikamenten und...

Basel, 23 October 2025  Group sales grew by 7%1 at constant exchange rates (CER; 2% in CHF) in the first nine months, driven by high demand for our innovative medicines and...

SOUTH SAN FRANCISCO, Calif., and NEW HAVEN, Conn., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Simcha Therapeutics (“Simcha”), a clinical-stage immunobiology company pioneering first-in-class cytokine...

Les réponses étaient rapides et durables, et une réduction tumorale a été observée chez 82 pour cent des patients1 Les nouveaux résultats issus de cette étude expérimentale s’appuient sur la solidité...